Literature DB >> 9848451

Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres.

A L Barry1, P C Fuchs, S D Brown.   

Abstract

An orally administered streptogramin (RPR 106,972) and a parenteral streptogramin (quinupristin/dalfopristin) were evaluated against a collection of 2481 recent clinical isolates of gram-positive cocci. The isolates were gathered from ten North American medical centres during the winter months of 1996-1997. In spite of minor differences, both streptogramins had essentially identical spectra of activity which included many erythromycin-resistant isolates. Previously proposed interpretative criteria for quinupristin/dalfopristin disc diffusion susceptibility tests were confirmed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9848451     DOI: 10.1093/jac/42.5.651

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci.

Authors:  C Betriu; M Redondo; M L Palau; A Sánchez; M Gómez; E Culebras; A Boloix; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.